Board meeting on 26 Oct 2026 to approve Q2 results

Profit growth above 25%EBITDA margin expansionResults View source PDF Explain this filing

VENUSREM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.4%Reaction day

₹1570.20

prior close

₹1587.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.6%+2.1% vs market

Pharmaceuticals peers, median of 172sector-0.6%+1.1% vs sector

On the reaction day the stock moved 2.1 pts more than Nifty Microcap 250 and 1.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.8

10m

-0.9

15m

-1.0

30m

-0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.4-1.6+2.1-0.6+1.1

Next day

+5.1-1.0+6.1-0.7+5.8

+1.9-2.6+4.5-1.9+3.8

-3.5-5.1+1.6-3.5-0.1

-7.9-6.1-1.8-4.3-3.6

-9.9-8.3-1.6-6.0-3.9

-11.6-6.4-5.2-2.8-8.7

15d

-8.5pendingpending-0.9-7.6

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Venus Remedies has informed exchanges that its Board of Directors will meet on 26 October 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2026. The trading window for designated persons remains closed from 1 October 2026 until 48 hours after the results are declared.

Likely market impact

Q2 FY27 results due on 26 Oct 2026; insider trading window closed till 48 hours post declaration.

By the numbersConsolidated · Q2 FY27 vs Q2 FY26

	Q2 FY27	Q2 FY26	Change
Revenue	₹218.8 Cr	₹192.8 Cr	+13.5%
Operating profit	₹32.96 Cr	₹24.78 Cr	+33.0%
Profit after tax	₹25.65 Cr	₹20.13 Cr	+27.4%
EBITDA margin	19.4%	16.1%	+3.4 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.